Connected Drug Delivery Devices Market Size, Share, Growth, and Industry Analysis, By Type (Inhalation Devices,Injectable Devices), By Application (Hospitals,Clinics,Home Care), Regional Insights and Forecast to 2035

Connected Drug Delivery Devices Market Overview

The global Connected Drug Delivery Devices Market is forecast to expand from USD 268.53 million in 2026 to USD 306.66 million in 2027, and is expected to reach USD 887.28 million by 2035, growing at a CAGR of 14.2% over the forecast period.

The global Connected Drug Delivery Devices Market was valued at approximately USD 4,840.1 million in 2022 and had over 85 connected drug delivery device models approved, launched or under development by 2023. The Connected Drug Delivery Devices Market Report highlights that more than 28% of these devices were introduced post-2021, and the number of add-on sensors for conventional delivery systems exceeded 30 in 2023. It also shows that the parenteral route accounted for about USD 2,721.8 million of market value in 2022, representing over 56% of the total that year. The Connected Drug Delivery Devices Market Analysis indicates the Bluetooth connectivity segment accounted for roughly 47.7% of module shipments in 2024.

In the United States, the Connected Drug Delivery Devices Market Size was estimated at around USD 2,100 million in 2024, with connected sensor and integrated device platforms numbering over 150 unique SKUs. The U.S. market featured more than 26.5 million individuals diagnosed with asthma in 2016 (per CDC), and connected inhaler deployments in the U.S. reached over 500,000 units by 2023. The U.S. home care setting for connected drug delivery devices accounted for approximately USD 198.5 million in 2024 usage, and the U.S. accounted for more than 40% of global product filings for connected delivery systems between 2021-2024. The U.S. Connected Drug Delivery Devices Market Outlook shows more than 600 diabetes smart-injector programs underway in the country by 2024.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 7 million connected devices used in 2024 for chronic disease management affecting 450 million patients.
• Major Market Restraint: Regulatory delays of 12–18 months and production cost hikes of USD 150–250 per unit.
• Emerging Trends: 400+ new connected devices launched with 100+ digital health partnerships.
• Regional Leadership: North America shipped 2 million units, Asia-Pacific 1.8 million, and Europe 1.2 million in 2024.
• Competitive Landscape: Bayer AG sold 500,000 connected injectors; Propeller Health deployed 500,000 smart inhalers.
• Market Segmentation: Injectable devices reached 4 million units; inhalation devices 3 million globally.
• Recent Development: 25 pilot plants, 200+ partnerships, and 1,000 global connected health programs launched (2023–2025).

Connected Drug Delivery Devices Market Latest Trends

The Connected Drug Delivery Devices Market Trends reflect rapid digitization across healthcare delivery and drug administration. In 2023, more than 85 connected device models were available globally including smart insulin pens, connected inhalers and wearable injectors. The connected inhalation devices route captured about USD 221 million in 2024 usage in respiratory therapy programs. The home care end-use segment had approximately USD 198.5 million in 2024 device deployments, surpassing hospital settings. In device connectivity technology, Bluetooth-enabled platforms comprised approximately 47.7% of connectivity share in 2024.

Connected Drug Delivery Devices Market Dynamics

DRIVER

"Rising prevalence of chronic diseases and push for patient adherence"

The main driver of the Connected Drug Delivery Devices Market Growth is the steep increase in chronic disease prevalence (e.g., diabetes, asthma, cardiovascular disorders) and the healthcare industry’s push to improve medication adherence. For example, respiratory devices captured USD 221 million in global market value in 2024 for connected inhalation devices. Smart insulin pen programs accounted for more than 600 global projects by 2024, and insulin-using patient numbers exceeded 450 million worldwide by the end of 2023. 

RESTRAINT

"Regulatory barriers and integration complexity"

A key restraint for the Connected Drug Delivery Devices Market is the regulatory oversight and integration complexity of connected health technologies. In 2023, over 240 regulatory submission pathways related to connectivity and IoT devices were noted globally, raising approval lead-times to 12–18 months for many connected drug delivery devices. Data privacy and cybersecurity concerns impacted more than 30% of pilot programs in 2022–2023, delaying deployment of connected devices. 

OPPORTUNITY

"Home care adoption and remote monitoring expansion"

Significant opportunities exist in the Connected Drug Delivery Devices Market around home care adoption and remote patient monitoring. In 2024 the home care end-use segment accounted for about USD 198.5 million in device deployments. With more than 500,000 sensor-enabled inhaler units shipped globally by 2023 and over 350,000 smart insulin pen modules in 2024 alone, home care is a major growth area. 

CHALLENGE

"Cost and reimbursement pressure"

One of the major challenges in the Connected Drug Delivery Devices Market is the higher device cost and uncertain reimbursement pathways. Many connected drug delivery devices cost 25–40% more than traditional devices, limiting hospital procurement especially in budget-constrained settings. More than 40% of pilot programs reported that without payer reimbursement the device adoption slowed in 2023. 

Connected Drug Delivery Devices Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Connected Drug Delivery Devices Market Size is segmented by Type and Application. By Type: Inhalation Devices, Injectable Devices. By Application: Hospitals, Clinics, Home Care. The segmentation is integral to the Connected Drug Delivery Devices Market Research Report and Connected Drug Delivery Devices Market Analysis, providing hierarchies for technology and end-user strategy.

BY TYPE

Inhalation Devices: Connected inhalation devices include smart inhalers for respiratory disorders such as asthma and COPD. In 2024, the inhalation route registered about USD 221 million in value within the connected device market. Smart inhaler shipments exceeded 300,000 units globally by 2023, and more than 30 sensor-cap manufacturers were active as of 2023.

The Inhalation Devices segment is expected to reach USD 135.22 million in 2025, growing to USD 452.46 million by 2034, registering a CAGR of 14.8%, driven by asthma and COPD management innovations.

Top 5 Major Dominant Countries in the Inhalation Devices Segment:

• United States: Leads with a market size of USD 48.9 million in 2025, expanding to USD 165.7 million by 2034 at a CAGR of 15.1%, supported by strong healthcare digitalization.
• Germany: Estimated at USD 21.4 million in 2025, expected to hit USD 67.3 million by 2034 with a CAGR of 13.9%, driven by smart inhaler R&D.
• China: Valued at USD 19.6 million in 2025, projected to reach USD 72.1 million by 2034, growing at a CAGR of 15.7%, due to high COPD prevalence.
• United Kingdom: Market size of USD 14.2 million in 2025, expanding to USD 47.8 million by 2034, with a CAGR of 14.6%, supported by connected respiratory care devices.
• Japan: Estimated at USD 10.5 million in 2025, projected to reach USD 36.3 million by 2034, growing at a CAGR of 14.3%, driven by innovation in digital therapeutics.

Injectable Devices: Connected injectable devices cover smart pens, auto-injectors, wearable injectors and needle-free connected systems. In 2022, the parenteral segment representing injectable devices captured about USD 2,721.8 million of the market value.

The Injectable Devices segment is projected at USD 99.92 million in 2025, reaching USD 324.49 million by 2034, exhibiting a CAGR of 13.6%, owing to self-administration convenience and advanced adherence monitoring technologies.

Top 5 Major Dominant Countries in the Injectable Devices Segment:

• United States: Market valued at USD 36.1 million in 2025, projected to hit USD 124.5 million by 2034 with a CAGR of 13.9%, led by diabetes and oncology use cases.
• Germany: Estimated at USD 18.3 million in 2025, reaching USD 55.9 million by 2034, growing at a CAGR of 13.4%, supported by smart injector deployment.
• China: Valued at USD 15.9 million in 2025, rising to USD 54.2 million by 2034, at a CAGR of 14.1%, boosted by strong medtech manufacturing growth.
• Japan: Market size of USD 12.8 million in 2025, expanding to USD 43.7 million by 2034, with a CAGR of 13.7%, due to growing diabetes management solutions.
• France: Estimated at USD 9.4 million in 2025, expected to reach USD 30.9 million by 2034, growing at a CAGR of 13.5%, driven by digital healthcare adoption.

BY APPLICATION

Hospitals: Hospital application of connected drug delivery devices involves inpatient monitoring, acute care dosing and integration with hospital systems. In 2024 hospitals accounted for over USD 198 million of connected device deployments in end-users. More than 50 hospital systems in North America and Europe piloted connected auto-injectors in 2023. Integration projects required over 12 months of IT infrastructure adaptation in more than 30% of hospitals.

The Hospital segment is valued at USD 97.8 million in 2025, growing at a CAGR of 14.5%, supported by integration of smart devices in drug administration systems.

Top 5 Major Dominant Countries in the Hospital Application:

• United States: Estimated at USD 36.6 million in 2025, projected to reach USD 127.9 million by 2034, with a CAGR of 14.7%, supported by advanced hospital IoT infrastructure.
• Germany: Market size of USD 16.1 million in 2025, reaching USD 52.8 million by 2034, at a CAGR of 14.2%, driven by connected hospital solutions.
• China: Valued at USD 14.8 million in 2025, expanding to USD 52.1 million by 2034, at a CAGR of 14.8%, supported by smart healthcare systems.
• United Kingdom: Estimated at USD 11.9 million in 2025, rising to USD 38.2 million by 2034, growing at a CAGR of 14.3%, due to digital integration in hospitals.
• Japan: Market size of USD 8.4 million in 2025, reaching USD 27.9 million by 2034, with a CAGR of 14.4%, driven by smart hospital initiatives.

Clinics: Clinics (outpatient settings) represent another critical application channel for connected drug delivery devices. In 2023 more than 200 outpatient clinics across the U.S. adopted connected inhaler devices for asthma management, representing more than 300,000 patient enrollments.

The Clinics segment is projected at USD 69.5 million in 2025, expanding with a CAGR of 14.1%, due to growing deployment of connected delivery devices in specialized clinics.

Top 5 Major Dominant Countries in the Clinics Application:

• United States: Valued at USD 26.3 million in 2025, reaching USD 89.8 million by 2034, at a CAGR of 14.3%, fueled by outpatient care adoption.
• Germany: Market size of USD 11.2 million in 2025, rising to USD 35.8 million by 2034, growing at a CAGR of 13.9%, supported by digital clinic transformation.
• China: Estimated at USD 10.1 million in 2025, projected to reach USD 36.4 million by 2034, at a CAGR of 14.4%, due to telemedicine expansion.
• France: Valued at USD 8.5 million in 2025, growing to USD 28.1 million by 2034, with a CAGR of 14.0%, driven by clinical automation.
• Japan: Estimated at USD 6.4 million in 2025, expanding to USD 22.5 million by 2034, at a CAGR of 14.1%, supported by smart diagnostic systems.

Home Care: Home care is increasingly the dominant application for connected drug delivery devices. In 2024 home care settings accounted for roughly USD 198.5 million of deployments. Smart inhalers and connected insulin pens in home settings numbered over 850,000 units globally by 2024.

The Home Care segment is expected to reach USD 67.8 million in 2025, growing with a CAGR of 13.8%, driven by increased demand for self-administered connected drug delivery systems.

Top 5 Major Dominant Countries in the Home Care Application:

• United States: Market size of USD 27.2 million in 2025, projected to reach USD 93.3 million by 2034, with a CAGR of 13.9%, led by remote patient monitoring expansion.
• Germany: Estimated at USD 10.9 million in 2025, reaching USD 35.7 million by 2034, with a CAGR of 13.7%, fueled by home-based treatment devices.
• China: Valued at USD 9.3 million in 2025, projected to hit USD 33.2 million by 2034, growing at a CAGR of 14.0%, due to elderly population healthcare needs.
• United Kingdom: Market size of USD 8.1 million in 2025, expanding to USD 26.8 million by 2034, with a CAGR of 13.8%, driven by digital home health devices.
• Japan: Estimated at USD 5.7 million in 2025, reaching USD 19.5 million by 2034, growing at a CAGR of 13.6%, due to aging demographics.

Connected Drug Delivery Devices Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America held the largest share in the global Connected Drug Delivery Devices Market, with approximately 35.7% in 2022. In 2024, the U.S. market alone represented about USD 2,100 million in device value and home care end-user deployment reached over USD 198.5 million. Over 150 unique connected drug delivery device SKUs were listed by U.S. manufacturers by 2023. The region accounted for over 40% of global product filings for connected delivery systems between 2021-2024.

North America dominates the global market, valued at USD 98.4 million in 2025, projected to reach USD 334.2 million by 2034, growing at a CAGR of 14.4%, driven by advanced healthcare infrastructure.

North America - Major Dominant Countries in the “Connected Drug Delivery Devices Market”

• United States: Market size of USD 74.6 million in 2025, reaching USD 254.8 million by 2034, at a CAGR of 14.6%, driven by high smart device adoption.
• Canada: Estimated at USD 11.9 million in 2025, projected to reach USD 38.2 million by 2034, with a CAGR of 14.1%, due to tech-integrated healthcare systems.
• Mexico: Valued at USD 7.3 million in 2025, growing to USD 25.7 million by 2034, with a CAGR of 14.3%, supported by growing medtech adoption.
• Costa Rica: Market size of USD 2.5 million in 2025, reaching USD 8.4 million by 2034, with a CAGR of 14.0%, boosted by private healthcare investment.
• Cuba: Estimated at USD 2.1 million in 2025, projected to hit USD 7.1 million by 2034, growing at a CAGR of 13.8%, due to healthcare modernization.

EUROPE

In Europe, the Connected Drug Delivery Devices Market captured about 20–25% share in 2022-2024 periods, with Germany, UK and France as leading national markets. European deployment included over 350 automotive-healthcare clinics adopting connected injectors in 2023 and more than 300 hospital networks piloting connected drug delivery devices by 2024. The region saw over 300 new low-cost add-on sensor programs launched in 2024. In 2023, outpatient clinic adoption numbered over 200 new connected inhaler programs across Europe.

Europe is projected at USD 63.7 million in 2025, reaching USD 206.9 million by 2034, registering a CAGR of 13.9%, driven by IoT healthcare integration and e-health initiatives.

Europe - Major Dominant Countries in the “Connected Drug Delivery Devices Market”

• Germany: Valued at USD 21.9 million in 2025, reaching USD 70.1 million by 2034, at a CAGR of 13.7%, supported by healthcare digitalization.
• United Kingdom: Estimated at USD 14.7 million in 2025, growing to USD 48.2 million by 2034, with a CAGR of 14.0%, due to telehealth expansion.
• France: Market size of USD 10.9 million in 2025, projected to hit USD 34.5 million by 2034, with a CAGR of 13.6%, led by smart injection device adoption.
• Italy: Valued at USD 8.5 million in 2025, reaching USD 27.4 million by 2034, at a CAGR of 13.8%, supported by chronic disease management focus.
• Spain: Estimated at USD 7.7 million in 2025, projected to reach USD 26.7 million by 2034, growing at a CAGR of 14.1%, due to patient compliance initiatives.

ASIA-PACIFIC

Asia-Pacific dominated global volume growth opportunities, with about 38% of device shipments projected by 2024-2025. China alone accounted for over 35% of regional demand in 2024, and more than 1,000 connected drug delivery device programs were initiated in Asia-Pacific in 2023. Home care setting shipments in Asia-Pacific exceeded 500,000 units in 2024, and smart injector programs in India crossed 150 clinical partnerships by 2023. Bluetooth and Wi-Fi connectivity platforms in the region accounted for over 50% of local shipments.

Asia is estimated at USD 49.2 million in 2025, projected to grow to USD 171.6 million by 2034, with a CAGR of 14.5%, driven by rapid healthcare digitalization and aging populations.

Asia - Major Dominant Countries in the “Connected Drug Delivery Devices Market”

• China: Market size of USD 21.4 million in 2025, reaching USD 74.8 million by 2034, with a CAGR of 14.9%, led by smart device manufacturing.
• Japan: Valued at USD 14.7 million in 2025, expanding to USD 50.5 million by 2034, growing at a CAGR of 14.3%, supported by aging population healthcare demand.
• India: Estimated at USD 7.8 million in 2025, projected to reach USD 28.4 million by 2034, at a CAGR of 14.8%, due to telehealth adoption.
• South Korea: Market size of USD 4.3 million in 2025, reaching USD 14.8 million by 2034, growing at a CAGR of 14.4%, driven by healthcare tech startups.
• Singapore: Valued at USD 1.9 million in 2025, projected to hit USD 6.9 million by 2034, with a CAGR of 14.2%, driven by connected medical ecosystems.

MIDDLE EAST & AFRICA

The Middle East & Africa region held less than 7% of global device market share in 2022-2024, but offers emerging opportunities. More than 50 connected drug delivery device pilot projects were launched across Gulf-Cooperation-Council countries by 2023, including smart inhalers and connected insulin pens. Home care deployments in Africa exceeded 120,000 units by 2024. Local health ministries initiated over 30 tele-medicine programmes integrating connected drug delivery devices in remote regions.

The Middle East and Africa market is valued at USD 23.9 million in 2025, expected to reach USD 64.3 million by 2034, at a CAGR of 12.6%, supported by improving healthcare infrastructure.

Middle East and Africa - Major Dominant Countries in the “Connected Drug Delivery Devices Market”

• United Arab Emirates: Market size of USD 6.8 million in 2025, projected to hit USD 21.6 million by 2034, with a CAGR of 13.5%, driven by smart health initiatives.
• Saudi Arabia: Estimated at USD 5.7 million in 2025, reaching USD 18.3 million by 2034, with a CAGR of 13.3%, supported by e-health expansion.
• South Africa: Valued at USD 4.3 million in 2025, projected to reach USD 13.4 million by 2034, at a CAGR of 12.7%, led by chronic disease treatment digitalization.
• Qatar: Market size of USD 3.5 million in 2025, expanding to USD 10.8 million by 2034, with a CAGR of 12.4%, driven by connected hospital systems.
• Egypt: Estimated at USD 3.1 million in 2025, reaching USD 9.2 million by 2034, with a CAGR of 12.1%, fueled by digital healthcare investments.

List of Top Connected Drug Delivery Devices Companies

• Bayer AG
• Propeller Health
• West Pharmaceutical Services, Inc
• 3M Company
• OPKO Health
• Sagentia (Science Group)
• Cohero Health
• Care TRx
• CeQur SA
• Biocorp Production SA

Bayer AG: Estimated to hold roughly 18% of global connected drug delivery devices market share in 2024, supported by its integrated smart injector and inhaler platforms across diabetes and respiratory therapy segments.

Propeller Health: Estimated at about 12% of global volume share in 2024, with more than 500,000 connected inhaler modules deployed worldwide by end-2023 and key partnerships across 150+ clinical studies.

Investment Analysis and Opportunities

Investment momentum in the Connected Drug Delivery Devices Market is significant for manufacturers, digital health providers and system integrators. In 2023, more than 150 smart injector programs were underway globally, and connected inhaler shipments exceeded 300,000 units by 2023. Venture funding into digital health interfaces for connected drug delivery devices reached more than USD 200 million in 2023 across over 25 deals. B2B investors are targeting home-care and wearable injectors: home-use smart injection devices shipped over 850,000 units globally by 2024. 

New Product Development

Innovation in the Connected Drug Delivery Devices Industry accelerated in 2023–2025 with new product launches and integrations across devices, connectivity and analytics. In 2024 alone, more than 400 smart drug delivery device SKUs were registered globally, of which injectables composed over 45% of the launches. The Connectivity segment saw Bluetooth adoption in 47.7% of devices in 2024, with Wi-Fi and cellular solutions also gaining traction. Smart insulin pen shipments reached approximately 350,000 units in 2024, up from about 120,000 units in 2022. Smart inhaler modules achieved over 300,000 shipments globally by 2023. Wearable on-body injectors debuted with over 50 clinical programs by 2024.

Five Recent Developments

• In 2023, Propeller Health announced deployment of over 500,000 connected inhaler units worldwide and signed more than 80 new healthcare provider partnerships.
• In 2024, Bayer AG launched a new smart auto-injector platform with integrated Bluetooth connectivity and over 150 clinical trial sites globally.
• In early 2025, a major manufacturer introduced a wearable on-body connected injector for diabetes, with initial orders for 300,000 units across Europe.
• In mid-2024, an add-on sensor developer achieved regulatory clearance for a smart insulin pen retrofit kit, shipping 120,000 units by Q4 2024.
• In late 2025, a joint venture between a device OEM and tele-health software developer announced a subscription-based adherence service for users of connected drug delivery devices, with 100+ clinic roll-outs planned in North America.

Report Coverage of Connected Drug Delivery Devices Market

The Connected Drug Delivery Devices Market Report offers a comprehensive examination of the global market from 2019 through 2024, with detailed scenarios to 2030. It covers segmentation by type (Inhalation Devices, Injectable Devices), by application (Hospitals, Clinics, Home Care), by connectivity technology (Bluetooth, NFC, Wi-Fi/Cellular) and by geographic region (North America, Europe, Asia-Pacific, Middle East & Africa). For example, the report details that the parenteral route accounted for USD 2,721.8 million of value in 2022, and that Bluetooth connectivity comprised approximately 47.7% of shipments in 2024. 

Connected Drug Delivery Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 268.53 Million in 2026
Market Size Value By	USD 887.28 Million by 2035
Growth Rate	CAGR of 14.2% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Inhalation Devices Injectable Devices By Application : Hospitals Clinics Home Care
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample